Search

Background: Doravirine is a non-nucleoside reverse transcriptase inhibitor recommended for the treatment of virologically suppressed and treatment naïve people living with HIV. The DRIVE-REAL study aimed to describe the characteristics, treatment patterns, and virological outcomes of doravirine users in a real-world cohort in the UK., Methods: A retrospective, observational, multi-centre chart review was conducted for 300 adults living with HIV initiating doravirine-containing antiretroviral therapy., Results: At baseline 83% of individuals were male, 45% aged ≥50 years, 65% white ethnicity. Median time since HIV diagnosis was 12 years. 96% were antiretroviral therapy-experienced, 87% had a HIV viral load <50 copies/ml, and 15% had resistance to at least one antiretroviral drug. 66% had comorbidities, most commonly depression (26%), and 70% were taking at least one co-medication. At six months, 94% ( n = 283/300) were still receiving doravirine. Viral load data were available for n = 266/300 individuals and 95% ( n = 253/266) had viral load <50 copies/ml., Conclusions: Individuals initiating doravirine in this cohort are predominantly treatment-experienced white middle-aged males, with a high frequency of comorbidities and co-medication. The majority of individuals at 6 months remained on doravirine and maintained or achieved HIV viral suppression. This study provides epidemiologic characteristics that can inform clinical care and subsequent hypothesis-testing studies., Competing Interests: Declaration of Conflicting interestThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Ana Milinkovic has received honoraria for consultancy and speaker services, as well as support for conference attendance from Gilead Sciences, MSD, Janssen and ViiV Healthcare. Prof. Yvonne Gilleece has received honoraria for consultancy and speaker services, as well as support for conference attendance from Gilead Sciences and ViiV Healthcare. Olivera Rajkovic-Hooley and Adam Moore are employees of Adelphi Real World, who received funding from MSD for this analysis/manuscript development. Charlotte O’ Halloran, Nipur Siani and William Hickey are employees of MSD (UK) Limited, London, UK and may own stock and/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA. Stuart Gaffney was an employee of MSD (UK) Limited, London, UK at the time the study was conducted. No other author disclosures or conflicts of interest to disclose.